Serm Immuno Fixation Electrophoresis as a Diagnostic Method for Monoclonal Gammopathies in Patients with Multiple Myeloma


  • Araz Muhammad Yousif
  • Nashwan Sleman Ablhad
  • Parween Abdulsamad Ismail



Multiple myeloma, M component, monoclonal gammopathy, serum immunofixation electrophoresis,


B cells clonal expansion (producing abnormal amounts of immunoglobulins) reflect conditions causes a group of disorders called monoclonal gammopathies. They may be appearing as a range of diseases that consist of multiple myelomas (MM). The aim of this research is to use quantify and identify monoclonal gammopathy by serum immunofixation electrophoresis (SIFE) beside the serum protein electrophoresis (SPEP) assay as a tumor marker in the diagnosis of suspected multiple myeloma cases. Serum samples were collected from 94 patients with MM, and 30 persons as control, SPEP and SIFE were used for both groups. M band determined and evaluated of M protein by the Hellabio instruments. The results of this study showed significant elevation (p<0.001) in the group of patients with MM compared to control as follows: 49 (52.13%) for IgG kappa, 23 (24.46%) for IgG lambda, 10 (10.63%) for IgA kappa, 4 (4.25%) for IgA lambda, 6 (6.38%) for IgM kappa, and 2 (2.12%) for IgG monoclonal gammopathy. SPEP ought to be proposed as the original test for the establishing of doubted cases of multiple myeloma. IFE is the gold mark now and ought to be performed to certify the existence of an M-protein and to diagnostic its light chain and heavy chain isotype, which also leads to increase the sensitivity of diagnosis in suspected multiple myeloma cases by using SIFE beside the SPEP assay and utilized for detection and quantification of monoclonal gammopathy.


Palumbo A, Anderson K. Medical progress: Multi¬ple myeloma. N Engl J Med. 364:1046-60, 2011.

Attaelmannan M, Levinson SS. Understanding and identifying monoclonal gammopathies .Clin Chem. 46(80):1230-38,2000.

Lugassy G, Shaham R, Nemets A., Ben-Dor D, NahlieliO. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: A new clinical entity. AJM.117(6):440-41,2004.

Riccardi A, Mora O, Tinelli C,Porta C, Danova M, Brugnatelli S, et al. Responseto first-line chemo¬therapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol. Eur J Cancer 39:31-37,2003.

Barosi G, Boccador M, Cavo M, Corradini P, Marchetti M, Massaia M, et al.Management of multiple myeloma and related-disorders:guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO).Haematologica. 89(6):717-41,2004.

Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, et al.Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J ClinOncol. 31(36): 4529-35,2013.

Dispenzieri A, Gertz MA, Therneau TM, Kyle RA. Retrospective cohort study of 148 patients with polyclonal gammopathy.Mayo Clinic Proceedings. 76:476-87,2001.

Sthaneshwar P, Nadarajan V, Maniam JAS,Nordinand N, Gin GG. Serum free light chains: diagnostic and prognostic value in multiple myeloma. ClinChem Lab Med. 47(9):1101–07,2009.

Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol. 121:749-57,2003.

Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, et al. International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 23: 215-24,2009.

Deveci K, Korkmaz S, Sancakdar E, Acibucu D, Alkan F, Terzi H, et al. The evaluation of serum protein and serum immunofixation electrophoresis results in patients with monoclonal and polyclonal gammopathy: A single center experience. Int J Blood Res Disord. 2(2):1-4,2015.

Dash NR, MohantyB. Multiple Myeloma: A case of atypical presentation on protein electrophoresis. Indian J ClinBiochem. 27(1):100-02,2012.

Tripathy S. The role of serum protein electrophoresis in the detection of multiple myeloma: An experience of a Corporate hospital. J ClinDiagn Res. 6(9): 1458-61,2012.

Dajak M. Recommendations for use of tumor markers in monoclonal gammopathies. J Med Biochem.26( 2):165-72,2007.

Willrich MAV, Katzmann JA. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias.ClinChem Lab Med. 1-13,2015.

Walker RE, Lawson MA, Buckle CH, Snowden JA, Chantry AD. Myeloma bone disease: pathogenesis, current treatments and future targets. Br Med Bull. 111:117-38,2014.

Kyle RA, Gertz MA, Witzig T, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo ClinProc 2003;78:21-33.

Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood.116(25):5501-06,2010.

O’connell TX, Horita TJ, Kasravi B. Understanding and interpreting serum protein electrophoresis. Am Fam Physician. 71(1):105-12, 2005.

The International Myeloma Working Group. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15(12):e538-48,2014.

Ludwig H, Milosavljevic D, Zojer N, Faint JM, Bradwell AR, Hübl W, et al.Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia.27(1):213-19,2013.

Katzmann J, Willrich MAV, Kohlhagen MC, Kyle RA, Murray DL, Snyder MR et al. Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays Clin Chem. 61(2):360-67,2015.

Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, et al. Multiple myeloma. J NatlComprCancNetw. 9(10): 1146-83,2011.

Buchner-Daley L, Brady-West D, McGrowder D. Clinical and biochemical profle of monoclonal gammopathies in Caribbean patients in a resource-limited setting. Asian Pac J Cancer Prev.13: 6501-04,2012.

Al-Farsi K. Multiple myeloma: an update. Oman Med J. 28(1):3-11,2013.

Boyle EM, Fouquet G, Guidez S, Bonnet S, Demarquette H, Dulery R, et al. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma. Cancer. 120:3952-57, 2014.

Keren DF. Protein electrophoresis in clinical diagnosis.Edward Arnold (Publishers) Ltd, 2003.

Cabarkapa V, Stoic Z, Deric M, Vucurevic-Ristic L, Drljaca M. The importance of free light chains of immunoglobulins determination in serum.JMB. 26 (4): 269-73.




How to Cite

A. M. Yousif, N. S. Ablhad, and P. A. Ismail, “Serm Immuno Fixation Electrophoresis as a Diagnostic Method for Monoclonal Gammopathies in Patients with Multiple Myeloma”, MJS, vol. 29, no. 4, pp. 43–49, May 2019.



Chemical Science